

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT
UPFRONT PAYMENT RECEIVED UNDER THE LICENSE
AGREEMENT WITH WINDWARD BIO AG FOR HBM9378/SKB378

This announcement is made by HBM Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

Reference is made to the announcement of the Company dated 10 January 2025, in relation to the entry into an exclusive license agreement (the “**Agreement**”) for HBM9378/SKB378, among the Company and Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“**Kelun-Biotech**”, stock code: 06990) as licensors and Windward Bio AG (“**Windward Bio**”) as the licensee.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company has received an upfront payment from Windward Bio in line with the Agreement, including both cash payment and an equity interest in the parent company of Windward Bio. The receipt of this upfront payment will further bolster the Company’s cash reserves.

Cautionary Statement: The Company cannot guarantee that it will be able to successfully develop or ultimately market its products referenced in the announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 6 March 2025

As at the date of this announcement, the Board comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson and Ms. Weiwei Chen as independent non-executive Directors.